{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:02:23Z","timestamp":1792623743239,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00894-026-06880-8","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:35:03Z","timestamp":1786091703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic basis of G595R-mediated resistance to entrectinib in TRK kinase: a structural-energetic perspective"],"prefix":"10.1007","volume":"32","author":[{"given":"Minyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoou","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"6880_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103451","volume":"165","author":"A Kojadinovic","year":"2021","unstructured":"Kojadinovic A, Laderian B, Mundi PS (2021) Targeting TRK: a fast-tracked application of precision oncology and future directions. Crit Rev Oncol Hematol 165:103451. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103451","journal-title":"Crit Rev Oncol Hematol"},{"key":"6880_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104234","volume":"194","author":"G Hagopian","year":"2024","unstructured":"Hagopian G, Nagasaka M (2024) Oncogenic fusions: targeting NTRK. Crit Rev Oncol Hematol 194:104234. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104234","journal-title":"Crit Rev Oncol Hematol"},{"key":"6880_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102733","volume":"127","author":"M Repetto","year":"2024","unstructured":"Repetto M, Chiara Garassino M, Loong HH, Lopez-Rios F, Mok T, Peters S, Planchard D, Popat S, Rudzinski ER, Drilon A, Zhou C (2024) NTRK gene fusion testing and management in lung cancer. Cancer Treat Rev 127:102733. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102733","journal-title":"Cancer Treat Rev"},{"key":"6880_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103893","volume":"79","author":"CA Manea","year":"2022","unstructured":"Manea CA, Badiu DC, Ploscaru IC, Zgura A, Bacinschi X, Smarandache CG, Serban D, Popescu CG, Grigorean VT, Botnarciuc V (2022) A review of NTRK fusions in cancer. Ann Med Surg (Lond) 79:103893. https:\/\/doi.org\/10.1016\/j.amsu.2022.103893","journal-title":"Ann Med Surg (Lond)"},{"key":"6880_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731\u2013747. https:\/\/doi.org\/10.1038\/s41571-018-0113-0","journal-title":"Nat Rev Clin Oncol"},{"key":"6880_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.apsb.2022.10.012","volume":"13","author":"G Wang","year":"2023","unstructured":"Wang G, Wu Y, Wu C, Shuai W, Jiang T, Wang A, Bu F, Sun Q, Ouyang L (2023) Rational design and crystallographic analysis of novel isoform-selective TRKA inhibitors for cancer therapy. Acta Pharm Sin B 13:440\u2013443. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.012","journal-title":"Acta Pharm Sin B"},{"key":"6880_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/nejmoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM (2018) Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children. N Engl J Med 378:731\u2013739. https:\/\/doi.org\/10.1056\/nejmoa1714448","journal-title":"N Engl J Med"},{"key":"6880_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1158\/1535-7163.MCT-17-0419","volume":"17","author":"KM Smith","year":"2018","unstructured":"Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman I, Bonvini P, Li G (2018) Antitumor activity of entrectinib, a pan-TRK, ROS1, and ALK inhibitor, in ETV6-NTRK3-positive acute myeloid leukemia. Mol Cancer Ther 17:455\u2013463. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0419","journal-title":"Mol Cancer Ther"},{"key":"6880_CR9","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","volume":"59","author":"M Menichincheri","year":"2016","unstructured":"Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P (2016) Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem 59:3392\u20133408. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00064","journal-title":"J Med Chem"},{"key":"6880_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","volume":"6","author":"M Russo","year":"2016","unstructured":"Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Nicolantonio FD, Bianchi AS, Li G, Siena S, Bardelli A (2016) Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov 6:36\u201344. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0940","journal-title":"Cancer Discov"},{"key":"6880_CR11","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1038\/s41401-025-01603-w","volume":"46","author":"N Li","year":"2025","unstructured":"Li N, Yang MY, Zhang MY, Liu N, Zhou AW, Chai ZT, Lu SY (2025) Exploring the distinct activation mechanisms of neuromedin B receptor through multiple replica molecular dynamics simulations and Markov state modeling. Acta Pharmacol Sin 46:3190\u20133203. https:\/\/doi.org\/10.1038\/s41401-025-01603-w","journal-title":"Acta Pharmacol Sin"},{"key":"6880_CR12","doi-asserted-by":"publisher","first-page":"16766","DOI":"10.1021\/acs.jmedchem.5c01619","volume":"68","author":"X Qiao","year":"2025","unstructured":"Qiao X, Zhu C, Lan X, Li M, Li N, Huang J, Liu N, Zhang J, Lu S (2025) Identification of an unexplored dynamic allosteric site on the activation pathway of the vasopressin V2 receptor. J Med Chem 68:16766\u201316780. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01619","journal-title":"J Med Chem"},{"key":"6880_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.915512","volume":"12","author":"H Zhuang","year":"2022","unstructured":"Zhuang H, Fan J, Li M, Zhang H, Yang X, Lin L, Lu S, Wang Q, Liu Y (2022) Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C. Front Oncol 12:915512. https:\/\/doi.org\/10.3389\/fonc.2022.915512","journal-title":"Front Oncol"},{"key":"6880_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/07391102.2019.1708798","volume":"39","author":"X Wu","year":"2021","unstructured":"Wu X, Li Q, Wan S, Zhang J (2021) Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with TrkA kinase. J Biomol Struct Dyn 39:202\u2013208. https:\/\/doi.org\/10.1080\/07391102.2019.1708798","journal-title":"J Biomol Struct Dyn"},{"key":"6880_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","volume":"7","author":"A Drilon","year":"2017","unstructured":"Drilon A, Siena S, Ou SHI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG (2017) Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7:400\u2013409. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1237","journal-title":"Cancer Discov"},{"key":"6880_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-0366-5_1","volume":"1137","author":"B Webb","year":"2014","unstructured":"Webb B, Sali A (2014) Protein structure modeling with MODELLER. Methods Mol Biol 1137:1\u201315. https:\/\/doi.org\/10.1007\/978-1-4939-0366-5_1","journal-title":"Methods Mol Biol"},{"key":"6880_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1021\/ct100578z","volume":"7","author":"MHM Olsson","year":"2011","unstructured":"Olsson MHM, S\u00d8ndergaard CR, Rostkowski M, Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical p K a predictions. J Chem Theory Comput 7:525\u2013537. https:\/\/doi.org\/10.1021\/ct100578z","journal-title":"J Chem Theory Comput"},{"key":"6880_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/wcms.1121","volume":"3","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer R, Case DA, Walker RC (2013) An overview of the Amber biomolecular simulation package. Wiley Interdiscip Rev Comput Mol Sci 3:198\u2013210. https:\/\/doi.org\/10.1002\/wcms.1121","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"6880_CR19","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015) ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11:3696\u20133713. https:\/\/doi.org\/10.1021\/acs.jctc.5b00255","journal-title":"J Chem Theory Comput"},{"key":"6880_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general Amber force field. J Comput Chem 25:1157\u20131174. https:\/\/doi.org\/10.1002\/jcc.20035","journal-title":"J Comput Chem"},{"key":"6880_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","volume":"79","author":"WL Jorgensen","year":"1983","unstructured":"Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926","journal-title":"J Chem Phys"},{"key":"6880_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cplett.2003.10.013","volume":"381","author":"X Wu","year":"2003","unstructured":"Wu X, Brooks BR (2003) Self-guided Langevin dynamics simulation method. Chem Phys Lett 381:512\u2013518. https:\/\/doi.org\/10.1016\/j.cplett.2003.10.013","journal-title":"Chem Phys Lett"},{"key":"6880_CR23","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an N.long(N)method for Ewald sums in large systems. J Chem Phys 98:10089\u201310092","journal-title":"J Chem Phys"},{"key":"6880_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"J-P Ryckaert","year":"1977","unstructured":"Ryckaert J-P, Ciccotti G, Berendsen HJC (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327\u2013341","journal-title":"J Comput Phys"},{"key":"6880_CR25","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, Hou T (2019) End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design. Chem Rev 119:9478\u20139508. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00055","journal-title":"Chem Rev"},{"key":"6880_CR26","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1093\/nar\/gkz499","volume":"47","author":"J Chen","year":"2019","unstructured":"Chen J, Wang X, Pang L, Zhang JZH, Zhu T (2019) Effect of mutations on binding of ligands to guanine riboswitch probed by free energy perturbation and molecular dynamics simulations. Nucleic Acids Res 47:6618\u20136631. https:\/\/doi.org\/10.1093\/nar\/gkz499","journal-title":"Nucleic Acids Res"},{"key":"6880_CR27","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.1080\/07391102.2023.2240421","volume":"42","author":"MT Hu","year":"2024","unstructured":"Hu MT, Ma WC, Wang JH, Jiang XQ, Yang DQ, Ao JY (2024) Mechanistic insights into the allosteric inactivation mechanism of ZAP-70 induced by the hot spot W165C mutation. J Biomol Struct Dyn 42:7600\u20137609. https:\/\/doi.org\/10.1080\/07391102.2023.2240421","journal-title":"J Biomol Struct Dyn"},{"key":"6880_CR28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1142\/S2737416524500182","volume":"23","author":"J Liu","year":"2024","unstructured":"Liu J, Jin Q, Xia J, Liu L, Liu Y, Jiang L (2024) Computational insights into the resistance of the gatekeeper mutation V564F of FGFR2 against pemigatinib. J Comput Biophys Chem 23:891\u2013900. https:\/\/doi.org\/10.1142\/S2737416524500182","journal-title":"J Comput Biophys Chem"},{"key":"6880_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1142\/S2737416525500541","volume":"25","author":"M Wu","year":"2026","unstructured":"Wu M, Zheng L, Qu X, Kang Y, Liu Y, Xu H, Jiang L, Kang Z (2026) Investigating the selective mechanism of inhibitors targeting G protein-coupled receptor kinase 5 (GRK5) relative to its highly homologous counterpart, GRK2. J Comput Biophys Chem 25:455\u2013466. https:\/\/doi.org\/10.1142\/S2737416525500541","journal-title":"J Comput Biophys Chem"},{"key":"6880_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51999-y","volume":"15","author":"M Li","year":"2024","unstructured":"Li M, Lan X, Shi X, Zhu C, Lu X, Pu J, Lu S, Zhang J (2024) Delineating the stepwise millisecond allosteric activation mechanism of the class C GPCR dimer mGlu5. Nat Commun 15:7519. https:\/\/doi.org\/10.1038\/s41467-024-51999-y","journal-title":"Nat Commun"},{"key":"6880_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.143324","volume":"310","author":"J Wei","year":"2005","unstructured":"Wei J, Chen F, Lu X, Fan J, Li M, Huang J, Liu N, Zhang J, Chai Z, Lu S (2005) In silico identification and experimental validation of long-range allosteric inhibition of Staphylococcus aureus Cas9 catalytic activity by an anti-CRISPR protein AcrIIA14. Int J Biol Macromol 310:143324. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143324","journal-title":"Int J Biol Macromol"},{"key":"6880_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41401-024-01385-7","volume":"46","author":"M-Y Zhang","year":"2025","unstructured":"Zhang M-Y, Ao J-Y, Liu N, Chen T, Lu S-Y (2025) Exploring the constitutive activation mechanism of the class A orphan GPR20. Acta Pharmacol Sin 46:500\u2013511. https:\/\/doi.org\/10.1038\/s41401-024-01385-7","journal-title":"Acta Pharmacol Sin"},{"key":"6880_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/17458080.2024.2442305","volume":"20","author":"G Xu","year":"2025","unstructured":"Xu G, Wu B, Liang W, Zhang J, Xu S, Du T, Li M, Zheng G, Zhou B, Wang Z, Liu W (2025) Computational revealing infigratinib resistance to the FGFR2 N549H and N549K mutations. J Exp Nanosci 20:2442305. https:\/\/doi.org\/10.1080\/17458080.2024.2442305","journal-title":"J Exp Nanosci"},{"key":"6880_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.150119","volume":"340","author":"H Tang","year":"2026","unstructured":"Tang H, Ao J, Zhang G, Wei J, Chai Z, Lu S (2026) Integrative computational simulations and functional assays decode allosteric dysregulation in a pathogenic SIRT6 variant. Int J Biol Macromol 340:150119. https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150119","journal-title":"Int J Biol Macromol"},{"key":"6880_CR35","doi-asserted-by":"publisher","unstructured":"Wang Y, Ji M, Zhou L, Zhang Q, Lu X, Liu N, Li X, Lu S (2005) Decoding the selective mechanism behind a monobody inhibitor to the phosphatase domain of SHP2: insights from molecular dynamics simulations. Phys Chem Chem Phys 27:9132\u20139142. https:\/\/doi.org\/10.1039\/d5cp00211g","DOI":"10.1039\/d5cp00211g"},{"key":"6880_CR36","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1007\/s11030-025-11340-1","volume":"30","author":"H Tang","year":"2026","unstructured":"Tang H, Ma W, Zhang G, Wei J, Ao J, Lu S (2026) Mechanistic basis of N-terminal domain-mediated allostery in SIRT6: integrating molecular dynamics simulations and biochemical assays. Mol Divers 30:3845\u20133856. https:\/\/doi.org\/10.1007\/s11030-025-11340-1","journal-title":"Mol Divers"},{"key":"6880_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/17458080.2023.2264521","volume":"18","author":"G Zheng","year":"2023","unstructured":"Zheng G, Liu W, Zhang Q, Shen T, Zhang J, Jiang L, Liang W, Zhou B, Liu L, Xu S, Li M (2023) Molecular docking and molecular dynamics simulations reveal the clinical resistance of the gatekeeper mutation V564F of FGFR2 against infigratinib. J Exp Nanosci 18:2264521. https:\/\/doi.org\/10.1080\/17458080.2023.2264521","journal-title":"J Exp Nanosci"},{"key":"6880_CR38","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1080\/07391102.2023.2225106","volume":"42","author":"X Qi","year":"2024","unstructured":"Qi X, Li G, Liu J, Mou L, Zhang Y, Guo S, Chen X, Li W (2024) Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1. J Biomol Struct Dyn 42:3010\u20133018. https:\/\/doi.org\/10.1080\/07391102.2023.2225106","journal-title":"J Biomol Struct Dyn"},{"key":"6880_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2025.102171","volume":"15","author":"G Zheng","year":"2025","unstructured":"Zheng G, Liu W, Kang Y, Xu B, Qiu X, Du T, Xu S, Chen R, Cheng H, Cai C (2005) Probing the role of zinc ion in metallo-\u03b2-lactamase inhibitor binding by using multiple molecular dynamics simulations. Results Chem 15:102171. https:\/\/doi.org\/10.1016\/j.rechem.2025.102171","journal-title":"Results Chem"},{"key":"6880_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020217","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang Y, Qiao X, Zhu R, Zhou L, Zhang Q, Lu S, Chai Z (2025) Computational elucidation of a monobody targeting the phosphatase domain of SHP2. Biomolecules 15:217. https:\/\/doi.org\/10.3390\/biom15020217","journal-title":"Biomolecules"},{"key":"6880_CR41","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/ct700119m","volume":"3","author":"J Shao","year":"2007","unstructured":"Shao J, Tanner SW, Thompson N, Cheatham TE (2007) Clustering molecular dynamics trajectories: 1. Characterizing the performance of different clustering algorithms. J Chem Theory Comput 3:2312\u20132334. https:\/\/doi.org\/10.1021\/ct700119m","journal-title":"J Chem Theory Comput"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-026-06880-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:51:43Z","timestamp":1789721503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-026-06880-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["6880"],"URL":"https:\/\/doi.org\/10.1007\/s00894-026-06880-8","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no ethical concerns regarding the approved decision.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"297"}}